BIOGEN INC (IDP.DE) Stock Price, Quote, News and Overview
FRA:IDP - Deutsche Boerse Ag - US09062X1037 - Common Stock - Currency: EUR
IDP.DE Quote, Performance and Key Statistics
BIOGEN INC
FRA:IDP (2/4/2025, 7:00:00 PM)
138.3
-0.8 (-0.58%)
The current stock price of IDP.DE is 138.3 EUR. In the past month the price decreased by -6.33%. In the past year, price decreased by -37.98%.
IDP.DE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 18.69 | 323.32B | ||
| AMG.DE | AMGEN INC | 14.96 | 149.57B | ||
| 1AMGN.MI | AMGEN INC | 14.81 | 148.09B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 937.76 | 118.34B | ||
| GIS.DE | GILEAD SCIENCES INC | 21.97 | 117.44B | ||
| ARGX.BR | ARGENX SE | N/A | 37.55B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 27.07B | ||
| 0QF.DE | MODERNA INC | N/A | 13.30B | ||
| 1MRNA.MI | MODERNA INC | N/A | 13.08B | ||
| ALEMS.BR | EUROPEAN MEDICAL SOLUTIONS S | N/A | 9.95B | ||
| GLPG.AS | GALAPAGOS NV | 6.98 | 1.44B | ||
| NVV1.DE | NOVAVAX INC | N/A | 1.30B |
Related stock screener links
About IDP.DE
Company Profile
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,570 full-time employees. The company has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. The company also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. The company commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.
Company Info
BIOGEN INC
225 Binney Street
Cambridge MASSACHUSETTS US
Employees: 7570
Company Website: https://www.biogen.com/
Investor Relations: https://investors.biogen.com
Phone: 17814642000
IDP.DE FAQ
What is the stock price of IDP.DE?
The current stock price of IDP.DE is 138.3 EUR.
What is the symbol for BIOGEN INC stock?
The exchange symbol of BIOGEN INC is IDP and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is IDP.DE stock listed?
IDP.DE stock is listed on the Deutsche Boerse Ag exchange.
Is IDP.DE a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for IDP.DE, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of IDP.DE.
Does IDP.DE stock pay dividends?
IDP.DE does not pay a dividend.
When does IDP.DE stock report earnings?
IDP.DE will report earnings on 2025-02-12, after the market close.
What is the Price/Earnings (PE) ratio of IDP.DE?
The PE ratio for IDP.DE is 8.75. This is based on the reported non-GAAP earnings per share of 15.8 and the current share price of 138.3 EUR.
IDP.DE Technical Analysis
IDP.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE. IDP.DE has an excellent profitability rating, but there are some minor concerns on its financial health.
IDP.DE Financial Highlights
Over the last trailing twelve months IDP.DE reported a non-GAAP Earnings per Share(EPS) of 15.8. The EPS decreased by 3.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.81% | ||
| ROA | 5.7% | ||
| ROE | 9.87% | ||
| Debt/Equity | 0.28 |
IDP.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 75% to IDP.DE. The Buy consensus is the average rating of analysts ratings from 42 analysts.
For the next year, analysts expect an EPS growth of 10.8% and a revenue growth -2.86% for IDP.DE